Clinical trials: Critical Illness With or Without Sepsis
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
Effect of Lactiplantibacillus Plantarum DAD-13 on Inflammatory Markers in ICU Sepsis Patients
This study investigated whether giving the probiotic Lactiplantibacillus plantarum DAD-13 to sepsis patients in the intensive care unit (ICU) could help reduce inflammation and improve bowel function.
- Conditions
- Sepsis, Systemic Inflammatory Response Syndrome (SIRS), Critical Illness
- Trial name
- LactoSepsis (NCT07072871)
- Testing
- Lactiplantibacillus plantarum DAD-13
- Where
- Indonesia
- Volunteers
- 32 people
- Sponsor
- PT Royal Medikalink Pharmalab
Sepsis
NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis
This Phase 2a study will evaluate the safety and efficacy of nogapendekin alfa inbakicept (NAI) plus standard of care compared with placebo plus standard of care in critically ill adults with sepsis and persistent lymphopenia.
- Trial name
- NCT07783789
- Testing
- Nogapendekin alfa inbakicept (NAI)
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
Sepsis, Critical Illness
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients
The goal of this clinical trial is to learn if a new medical device that sends electrical signals to the thigh muscles is safe and easy to use for people in the ICU (Intensive Care Unit) who are at risk of losing muscle strength.
- Conditions
- Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness
- Trial name
- ICUAW (NCT07362862)
- Testing
- Electrical Muscle Stimulation System
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Health Discovery Labs
Sepsis, Septic Shock
NAI for Sepsis With Persistent Lymphopenia
This is a Phase 2, randomized, open-label study evaluating the safety and efficacy of nogapendekin alfa inbakicept (NAI, ANKTIVA®) in combination with standard of care versus standard of care alone in critically ill adults with…
- Conditions
- Sepsis, Septic Shock, Lymphopenia, Immunosuppression
- Trial name
- NCT07578558
- Testing
- Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC)
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Critical Illness, Acute Kidney Injury
Collective Accuryn Physiologic Signals and Signatures
The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device.
- Conditions
- Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock
- Trial name
- CAPSS (NCT03817281)
- Testing
- Accuryn Monitoring System
- Where
- United States
- Sponsor
- Potrero Medical